U.S. Compounding Pharmacies Market Ecosystem, By Product Type, By Compounding Type, By Application (Pediatric, Adult, Geriatric, Veterinary), By Sterility, By Pharmacy Type, and By Therapeutic Area - Forecast to 2027

Analysis on U.S. Compounding Pharmacies Market – Ecosystem

This report evaluates “Global U.S. Compounding Pharmacies Market - Ecosystem” by studying Ecosystem analysis, trend intelligence and market revenue analysis. The compounding of medications is performed by pharmacists only if a specialized drug combination is needed for specific patients. The U.S. compounding pharmacies market - ecosystem was USD 4,861.4 Mn in the year 2019 and is expected to reach USD 7,304.46 Mn by the year 2027, growing at a CAGR of 5.2% during the forecast period. Compounding medications allow a physician to prescribe personalized medications prepared by a pharmacist for individuals.

In the U.S., around 56,000 community-based pharmacies are in operation, according to IACP. Apart from community-based pharmacies, there are around 7500 specialized compounding pharmacies, of which 3000 pharmacies make sterile products. The compounding program by the FDA ensures the availability of safe, effective, and lawfully marketed drugs to patients. Around 46 new medicines were approved by the U.S. FDA and Center for Drug Evaluation and Research (CDER) in the year 2017. The rise in the prevalence of chronic diseases in the U.S. also has a positive impact on the growth of the U.S. Compounding Pharmacies Market.

COVID-19 Impact Analysis & Opportunities in US Compounding Pharmacies Market

The outbreak of COVID-19 has bought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for US Compounding Pharmacies industry. Overall competitive landscape and market dynamics of US Compounding Pharmacies has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of US Compounding Pharmacies market.

Get a Free Sample Copy of the report at https://www.alltheresearch.com/sample-request/408

Ecosystem Snapshot of U.S. Compounding Pharmacies Market

U.S. Compounding Pharmacies Market Segmentation

Product type	Compounding type	Application	Sterility	Pharmacy type	Therapeutic Area
Oral Medication	Pharmaceutical Ingredient Alteration	Pediatric	Sterile	503 A	Hormone Replacement Therapy
Topical Medication	Currently Unavailable Pharmaceutical Manufacturing	Adult	Non- Sterile	503 B	Pain Management
Mouthwashes	Pharmaceutical Dosage Alteration	Geriatric			Dermatology
Suppositories	Others	Veterinary			Oncology
Injectables					Hematology
					Dental
					Others

On the basis of product type, the U.S. Compounding Pharmacies Market is categorized into oral medication, topical medication, mouthwashes, suppositories, and injectable. The oral medications segment dominated the market in 2019 with a share of 39.6% and is expected to account for a share of 40% in 2027. High demand for easy to administer dosage forms such as capsules, oral liquids, and granules will drive the growth of the segment. Rising health awareness and increasing demand for oral medication as the most preferred route of administration are projected to fuel the demand for oral medications over the forecast period.

In the Compounding type segment, the pharmaceutical ingredient alteration segment dominated the U.S. Compounding Pharmacies Marketing the year 2019 with a share of 35.6%. It is anticipated to grow with the highest CAGR of 5.9% over the forecast period.

In the U.S, the usage of compounding medication is higher among adults. This has resulted in the rapid growth of theU.S. Compounding Pharmacies Market, especially in the adult segment that was valued atUS$ 2,368.3Mn in the year 2019. The adult population in the United States demanded similar kinds of compounded medications, where medications for chronic pain therapies and hormone replacement therapies were the most preferred ones. On an average, the U.S. households spend USD 338 yearly on over the counter products. The majority of adult population in the United States use over the counter medicines as the first response to minor ailments.

The U.S. Compounding Pharmacies Market is categorized into 503A and 503B on the basis of pharmacy type. 503A has historically focused on compounding different topical cream products for pain management and on modifying the route of administration of other medications. 503As compounding pharmacies are not governed as strictly as 503Bs from a manufacturing viewpoint. 503Bs offer cheaper and more competitive alternatives to the conventional 503A model, allowing 503Bs to become a part of the hospital's drug supply chain. The 503B segment in the U.S. Compounding Pharmacies Market is expected to grow at a CAGR of 7.6% from 2019 to 2026. At present, only 73 FDA registered 503b facilities are present in the U.S.

On the basis of sterility, the U.S. Compounding Pharmacies market is segmented into Sterile and Non-sterile. Sterile compounding refers to the development of medications in an atmosphere that is free from bacteria, viruses, or any other infectious microorganisms. This kind of compounding is generally used for medications to be used through an IV injection or to be applied directly into the eyes of the patient. Administering medications through the aforementioned routes can pose the risk of developing infections, and thus, sterile compounding techniques help in reducing such risks significantly. The sterile segment is projected to witness an overall incremental growth of US$ 552.2 Mn between 2019 and 2027.

Non-sterile compounding involves creating medications in a clean environment, but it does not require the environment to be completely free from all microorganisms. These Non-sterile compounding medications can be consumed orally in the form of pills or as the liquid. In comparison to the medications that are injected, the risk involved in the oral ones is low. This factor contributes to the growth of the Non-sterile segment in the U.S. Compounding Pharmacies Market.

The Major Key Players operating in the U.S. Compounding Pharmacies market are as follows:

Company	Ecosystem Positioning	Total Revenue 2018 (US$ Mn)	Region
Fresenius Kabi	Product Manufacturer	$ 18,339.29 Million	Global
Fagron NV	Product Manufacturer	$ 532.1Million	Global
Clinigen Group	Product Manufacturer	$ 530Million	Global
Central Admixture Pharmacy Services	Product Manufacturer	$ 257.1 Million	Global
PharMEDium Services, LLC	Product Manufacturer	$ 209 Million	Global

A Glance on U.S. Compounding Pharmacies Market Ecosyetm Key Trends:
 

Trends	Compounding Type	Short Term	Mid-Term	Long Term
Dose alteration for adults according to individual needs is not available in the standardized doses manufactured by most pharma companies. This factor is driving the compounding pharmacies market.	Pharmaceutical Dose Alteration	High	High	High
High preference for compounded drugs among adult and geriatric age groups	XX
An increase in bulk manufacturing by compounding pharmacies catering the hospital sector	503B	Medium	Medium	Medium

 

 

Related Reports